Emergent BioSolutions reported third quarter 2026 results that met the low end of management's own guidance but missed analyst consensus, primarily due to significant volume declines in its Naloxone and Smallpox franchises. Consequently, the company lowered its full-year 2026 outlook for total revenues and Adjusted EBITDA.
Key Highlights
- Revenue Contraction: Total revenue fell 52% year-over-year to $110 million, missing the $123.2 million consensus estimate as core product segments faced timing and pricing headwinds.
- Narcan Pressure: Naloxone sales declined 42% to $43.5 million, driven by an unfavorable price-volume mix in U.S. public interest channels despite growth in the Canadian market.
- MCM Volatility: Smallpox MCM revenue dropped 68% to $26.7 million, reflecting the inherent volatility in the timing of U.S. government purchase options and deliveries.
- Guidance Downgrade: Management lowered full-year 2026 revenue guidance to $600M–$645M (from $645M–$675M) and Adjusted EBITDA to $110M–$140M (from $130M–$150M).
- Leadership Transition: CFO Rich Lindahl announced his retirement effective December 31, 2026, with Treasurer Frank Vargo named as the interim successor.